Deal Watch: Teva and Celltrion Announce Biosimilar Commercial Partnership

Biosimilar News  •  Deal Watch

Teva Pharmaceutical Industries Ltd., Celltrion, Inc. and Celltrion Healthcare announced that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s biosimilar candidates: CT-P10, a proposed mAb biosimilar to Rituxan (rituximab), and CT-P6, a proposed mAb biosimilar to Herceptin (trastuzumab).

Stay tuned to the Big Molecule Watch for further developments.

 

Download PDF

Comments are closed.